

DIN EN ISO 14155:2020-12 (E)

Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2020)

Contents	Page
European foreword	5
Annex ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered	7
Annex ZB (informative) Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered	9
Foreword	11
1 Scope	12
2 Normative references	12
3 Terms and definitions	12
4 Summary of good clinical practice (GCP) principles	20
5 Ethical considerations	21
5.1 General	21
5.2 Improper influence or inducement	21
5.3 Compensation and additional health care	21
5.4 Registration in publicly accessible database	22
5.5 Responsibilities	22
5.6 Communication with the ethics committee (EC)	22
5.6.1 General	22
5.6.2 Initial EC submission	22
5.6.3 Information to be obtained from the EC	23
5.6.4 Continuing communication with the EC	23
5.6.5 Continuing information to be obtained from the EC	23
5.7 Vulnerable populations	23
5.8 Informed consent	24
5.8.1 General	24
5.8.2 Process of obtaining informed consent	24
5.8.3 Special circumstances for informed consent	25
5.8.4 Information to be provided to the subject	26
5.8.5 Informed consent signature	28
5.8.6 New information	28
6 Clinical investigation planning	28
6.1 General	28
6.2 Risk management	29
6.2.1 General	29
6.2.2 Investigational device including clinical procedure risks and their disclosure	29
6.2.3 Clinical investigation process	29
6.3 Justification for the design of the clinical investigation	30
6.4 Clinical investigation plan (CIP)	30
6.5 Investigator's brochure (IB)	30
6.6 Case report forms (CRFs)	31
6.7 Monitoring plan	31
6.8 Investigation site selection	32

6.9	Agreement(s)	32
6.10	Labelling	32
6.11	Data monitoring committee (DMC)	32
7	Clinical investigation conduct	33
7.1	General	33
7.2	Investigation site initiation	33
7.3	Investigation site monitoring	33
7.4	Adverse events and device deficiencies	33
7.4.1	Signals requiring immediate action	33
7.4.2	Adverse events	34
7.4.3	Device deficiencies	34
7.4.4	Risk assessment process for potentially unacceptable risks	34
7.5	Clinical investigation documents and documentation	35
7.5.1	Amendments	35
7.5.2	Subject identification log	35
7.5.3	Source documents	36
7.6	Additional members of the investigation site team	36
7.7	Subject privacy and confidentiality of data	36
7.8	Document and data control	36
7.8.1	Traceability of documents and data	36
7.8.2	Recording of data	36
7.8.3	Electronic clinical data systems	37
7.9	Investigational device accountability	38
7.10	Accounting for subjects	38
7.11	Auditing	38
8	Suspension, termination, and close-out of the clinical investigation	39
8.1	Completion of the clinical investigation	39
8.2	Suspension or premature termination of the clinical investigation	39
8.2.1	Procedure for suspension or premature termination	39
8.2.2	Procedure for resuming the clinical investigation after temporary suspension	40
8.3	Routine close-out	40
8.4	Clinical investigation report	41
8.5	Risk assessment and conclusions	41
8.6	Document retention	42
9	Responsibilities of the sponsor	42
9.1	Clinical quality management	42
9.2	Clinical investigation planning and conduct	42
9.2.1	Selection and training of clinical personnel	42
9.2.2	Preparation of documents and materials	43
9.2.3	Conduct of clinical investigation	44
9.2.4	Monitoring	44
9.2.5	Safety evaluation and reporting	47
9.2.6	Clinical investigation close-out	48
9.3	Outsourcing of duties and functions	48
9.4	Communication with regulatory authorities	48
10	Responsibilities of the principal investigator	49
10.1	General	49
10.2	Qualification of the principal investigator	49
10.3	Qualification of investigation site	49
10.4	Communication with the EC	49
10.5	Informed consent process	50
10.6	Compliance with the CIP	50
10.7	Medical care of subjects	51
10.8	Safety reporting	52
	Annex A (normative) Clinical investigation plan (CIP)	53
	Annex B (normative) Investigator's brochure (IB)	62

Annex C (informative) Case report forms (CRFs)	65
Annex D (normative) Clinical investigation report	67
Annex E (informative) Essential clinical investigation documents	72
Annex F (informative) Adverse event categorization	79
Annex G (informative) EC responsibilities	81
Annex H (informative) Application of ISO 14971 to clinical investigations	85
Annex I (informative) Clinical development stages	86
Annex J (informative) Clinical investigation audits	91
Bibliography	94